Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only true global association dedicated to the multi-disciplinary study of lung cancer.

Regulatory Agency Perspective

Add ILCN as a preferred source

September 1, 2016

NCI Corner – Interview with Dinah S. Singer, PHD

Regulatory Agency Perspective

By Erik J. MacLaren, PhD Blue Ribbon Panel of the US National Cancer Advisory BoardDuring his State of the Union address in January 2016, President Barack Obama announced a new effort led by Vice President Joe Biden to accelerate research into cancer, known as the Vice President’s Cancer Initiative, or the National Cancer Moonshot.1 Among…
June 1, 2016

Small Cell Lung Cancer: The Next Challenge

Regulatory Agency Perspective

By Peter Ujhazy, MD, PhD The newfound optimism in the management of lung cancer that infused the research, clinical, and patient communities 12 years ago is still gaining momentum. Seminal findings on the predictive value of epidermal growth factor receptor mutations1,2 were followed by discoveries of other therapeutic targets (ALK, ROS1, BRAF, etc.) and by…
June 1, 2016

Interview with Richard Pazdur, MD

Regulatory Agency Perspective

New oncology drugs have, for decades, followed a well-trodden path of sequential clinical trials to get from the laboratory to the patient. This model has proven its worth by delivering effective new treatments while also protecting patient safety, but newer “seamless” trial designs have the potential to modernize the drug testing process and allow patients…
April 6, 2016

FDA Corner – Interview with Gideon Blumenthal, MD

Regulatory Agency Perspective

By Erik J. Mac Laren, PhD In 2015, the US Food and Drug Administration (FDA) approved an unprecedented 7 new drugs or new uses for drugs for patients with lung cancer, an increase driven by the proliferation of targeted therapies in the area of thoracic oncology. The advent of precision medicine in oncology has raised…
April 1, 2016

NCI Corner – Interview with Shakun Malik, MD

Regulatory Agency Perspective

By Erik J. Mac Laren, PhD In late 2015, the US National Cancer Institute (NCI) Thoracic Malignancy Steering Committee (TMSC) published its strategic priorities for the coming years. These include: (1) innovative clinical trials to facilitate the development of immunotherapies and targeted therapies; (2) rapid testing of new agents to treat small cell lung cancer…

Regulatory Agency Perspective

NCI Corner – Interview with Dinah S. Singer, PHD

Small Cell Lung Cancer: The Next Challenge

Interview with Richard Pazdur, MD

FDA Corner – Interview with Gideon Blumenthal, MD

NCI Corner – Interview with Shakun Malik, MD

COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

No “Known” Risk Factors: The Health Consequences of Radiation Therapy

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

No PFS, OS Benefit Seen in Final Results from PACIFIC-2

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

A Holistic Approach to Patient Care